It is applicable for monitoring a variety of NPM1 mutations [49], as well as DNMT3A and IDH mutations [50] in AML at the time of CR with the possibility to monitor several mutations simultaneously. This evidence concerns the gene IDH2 and acute myeloid leukemia.